Heterogeneity of the psychoses: Is there a neurodegenerative psychosis?

Schizophrenia Bulletin

Volumn 24, Issue 3, 1998, Pages 365-379

  Knoll IV, James L ^b   Garver, David L ^a,b   Ramberg, Jane E ^d   Kingsbury, Steven J ^b   Croissant, Deborah ^b   McDermott, Barbara ^c  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Tulane University Medical School ^*

Author keywords

Apoptosis; Degeneration; Drug response; Evoked cortical response; Heterogeneity; Phosphoesters; Ventricular brain ratio

Indexed keywords

GLUTAMIC ACID; NEUROTROPHIC FACTOR;

AGE; APOPTOSIS; ARTICLE; BRAIN DEGENERATION; BRAIN SIZE; CLINICAL FEATURE; EVOKED CORTICAL RESPONSE; HUMAN; NERVE CELL DEGENERATION; NEUROPHYSIOLOGY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0031846259     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033332     Document Type: Article

References (99)

1. 2 activity in serum of neuroleptic-naive psychiatric inpatients. Pharmacopsychiatry, 26:94-98 1993.
2. Anderson, D.K., and Thomas, C.E. Mechanisms and the role of oxygen free radicals in CNS pathology. In: Racagni, G.; Brunello, N.; and Langer, S.Z., eds. Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. Basel, Switzerland: Karger, 1994. pp. 119-124.
3. Artman, H.; Grau, H.; Adelman, M.; and Schleiffer, R. Reversible and non-reversible enlargement of cerebrospinal fluid spaces in anorexia nervosa. Neurobiology, 27:304-312, 1985.
4. Barde, Y.A. Neurotrophins: A family of proteins supporting the survival of neurons. Progress in Clinical and Biological Research, 390:45-56, 1994.
5. Barron, S.A.; Jacobs, L.; and Kinkel, W.R. Changes in size of normal lateral ventricles during aging determined by computerized tomography. Neurology, 26:1011-1013, 1976.
6. Bersani, G.; Aloe, L.; Iannitelli, A.; Maselli, P.; Venturi, P.; Garavini, A.; Angelucci, F.; Bracci-Laudiero, L.; and Pancheri, P. Low nerve growth factor (NGF) plasma levels in schizophrenic patients: A pilot study. Schizophrenia Research, 18:159-160, 1996.
7. Breier, A.; Schreiber, J.L.; Dyer, J.; and Pickar, D. National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Archives of General Psychiatry, 48:239-246, 1991.
8. Carlen, P.L.; Wortzman, G.; Holgate, R.C.; Wilkinson, D.A.; and Rankin, G. Reversible cerebral atrophy in recently abstinent chronic alcoholics measured by computed tomography scans. Science, 200:1076-1078, 1978.
9. Chakos, M.H.; Lieberman, J.A.; Bilder, R.M.; Borenstein, M.; Lerner, G.; Bogerts, B.; Wu, H.; Kinon, B.; and Ashtari, M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry, 151:1430-1436, 1994.
10. Chang, W.H.; Chen, T.Y.; Lin, S.K.; Lung, F.W.; Lin, W.L.; Hu, W.H.; and Yeh, E.K. Plasma catecholamine metabolites in schizophrenics: Evidence for the two-subtype concept. Biological Psychiatry, 27:510-518, 1990.
11. Chang, W.H.; Hwu, H.G.; Chen, T.Y; Lin, S.K.; Lung, F.W.; Chen, H.; Lin, W.L.; Hu, W.H.; Lin, H.N.; and Chien, C.P. Plasma homovanillic acid and treatment response in a large group of schizophrenic patients. Schizophrenia Research, 10:259-265, 1993.
12. Coffman, J.A. Computed tomography. In: Andreasen, N.C., ed. Brain Imaging: Application in Psychiatry. Washington, DC: American Psychiatric Association Press, 1989. pp. 1-65.
13. Coffman, J.A., and Nasrallah, H.A. Relationships between brain density, cortical atrophy and ventriculomegaly in schizophrenia and mania. Acta Psychiatrica Scandinavica, 72:126-132, 1985.
14. Collins, R.C., and Olney, J.W. Focal cortical seizures cause distant thalamic lesions. Science, 218:177-179, 1982.
15. Conrad, A.J., and Scheibel, A.B. Schizophrenia and the hippocampus: The embryological hypothesis extended. Schizophrenia Bulletin, 13(4):577-587, 1987.
16. Cotran, R.S.; Kuman, V.; and Robbins, S.L., eds. Pathologic Basis of Disease. 4th ed. Philadelphia, PA: W.B. Saunders and Company, 1989. pp. 1-38.
17. Cowan, W.M.; Fawcett, J.W.; O'Leary, D.D.M.; and Stanfield, B.B. Regressive events in neurogenesis. Science, 225:1258-1265, 1984.
18. Crow, T.J. Two dimensions of pathology in schizophrenia: Dopaminergic and non-dopaminergic. Psychopharmacology Bulletin, 18(1):22-29, 1982.
19. D'Amato, T.; Rochet, T.; Dalery, J.; Chauchat, J.H.; Terra, J.L.; Arteaga, C.; and Marie-Cardine, M. X-ray computed tomographic abnormalities in schizophrenia: Trial of relationship with clinical data. Encephale, 18:175-179, 1992.
20. Davis, K.L. "Ventricular Enlargement in Poor Outcome Schizophrenia: Support for Asymmetric Age Dependent Change." Paper presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1996.
21. Deakin, J.F.W.; Slater, P.; Simpson, M.D.C.; Gilchrist, A.C.; Skan, W.J.; Royston, M.C.; Reynolds, G.P.; and Cross, A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. Journal of Neurochemistry, 52:1781-1786, 1989.
22. 31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biological Psychiatry, 36:503-510, 1994.
23. DeLisi, L.E.; Stritzke, P.; Riordan, H.; Holan, V.; Boccio, A.; Kushner, M.; McClelland, J.; Van Eyl, O.; and Annand, A. The timing of brain morphological changes in schizophrenia and their relationship to clinical outcome. Biological Psychiatry, 31:241-254, 1992.
24. DeLisi, L.E.; Tew, W.; Xie, S.; Hoff, A.L.; Sakuma, M.; Kushner, M.; Lee, G.; Shedlack, K.; Smith, A.M.; and Grimson, R. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: Preliminary findings. Biological Psychiatry, 38:349-360, 1995.
25. Edelman, G.M., and Chuong, C.M. Embryonic to adult conversion of neural cell adhesion molecules in normal and staggerer mice. Proceedings of the National Academy of Sciences of the United States of America, 79:7036-7040, 1982.
26. Feinberg, I. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence? Journal of Psychiatric Research, 17:319-334, 1982/83.
27. Frecska, E.; Losonczy, M.F.; Keefe, R.E.; Song, I.S.; Rotter, M.; Apter, S.; Guo, L.; Davidson, M.; Mohs, R.C.; and Davis, K.L. Ventricular enlargement in poor outcome schizophrenia: Support for asymmetric age dependent change. [Abstract] American College of Neuropsychopharmacology, 34:74, 1995.
28. 31P magnetic resonance chemical shift imaging. Acta Psychiatrica Scandinavica, 86:455-462, 1992.
29. Garver, D.L.; Kelly, K.; Fried, K.A.; Magnusson, M.; and Hirschowitz, J. Drug response patterns as a basis of nosology for the mood-congruent psychoses (the schizophrenias). Psychological Medicine, 18:873-885, 1988.
30. Garver, D.L.; Reich, T.; Isenberg, K.E.; and Cloninger, C.R. Schizophrenia and the question of genetic heterogeneity. Schizophrenia Bulletin, 15(3):421-430, 1989.
31. Garver, D.L.; Steinberg, J.L.; McDermott, B.E.; Yao, J.K.; Ramberg, J.E.; Lewis, S.; and Kingsbury, S.J. Etiologic heterogeneity of the psychoses: Is there a dopamine psychosis? Neuropsychopharmacology, 16(3):191-201, 1997.
32. 2 activity in schizophrenia: A replication study. Biological Psychiatry, 28:495-501, 1990.
33. 2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biological Psychiatry, 22:421-426, 1987.
34. 2 activity in schizophrenia. Schizophrenia Research, 16:1-6, 1995.
35. Gewirtz, G.; Squires-Wheeler, E.; Sharif, Z.; and Honer, W.G. Results of computerised tomography during first admission for psychosis. British Journal of Psychiatry, 164:789-795, 1994.
36. Glen, A.I.M.; Glen, E.M.T.; Horrobin, D.F.; Vaddadi, K.S.; Spellman, M.; Morse-Fisher, N.; Ellis, K.; and Skinner, F.S. A red cell membrane abnormality in a sub-group of schizophrenic patients: Evidence for two diseases. Schizophrenia Research, 112:53-61, 1994.
37. Goetz, K.L., and van Kammen, D.P. Computerized axial tomography scans and subtypes of schizophrenia: A review of the literature. Journal of Nervous and Mental Disease, 141:31-41, 1986.
38. 3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics. Biological Psychiatry, 37:175-182, 1995.
39. Hollister, J.M.; Laing, P.; and Mednick, S.A. Rhesus incompatibility as a risk factor for schizophrenia in male adults. Archives of General Psychiatry, 53:19-24, 1996.
40. Horrobin, D.F.; Manku, M.S.; Hillman, H.; Iain, A.; and Glen, M. Fatty acid levels in the brains of schizophrenics and normal controls. Biological Psychiatry, 30:795-805, 1991.
41. Huttenlocher, P.R. Synaptic density in human frontal cortex: Developmental changes and effects of aging. Brain Research, 163:195-205, 1979.
42. Jaskiw, G.E.; Juliano, D.M.; Goldberg, T.E.; Hertzman, M.; Urow-Hamell, E.; and Weinberger, D.R. Cerebral ventricular enlargement in schizophreniform disorder does not progress: A seven year follow-up study. Schizophrenia Research, 14:23-28, 1994.
43. Kaiya, H.; Horrobin, D.F.; Manku, M.S.; and Morse-Fisher, N. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biological Psychiatry, 30(4):357-362, 1991.
44. Kaplan, M.J.; Lazoff, M.; Kelly, K.; Lukin, R.; and Garver, D.L. Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics. Biological Psychiatry, 27:205-214, 1990.
45. Kato, T.; Shioiri, T.; Murashita, J.; Hamakawa, H.; Inubushi, T.; and Takahashi, S. Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Research: Neuroimaging, 61(3):151-160, 1995.
46. Kemali, D.; Maj, M.; Galderisi, S.; Milici, N.; and Salvati, A. Ventricle-to-brain ratio in schizophrenia: A controlled follow-up study. Biological Psychiatry, 26:756-759, 1989.
47. Kerr, J.F.; Wyllie, A.H.; and Currie, A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer, 26:239-257, 1972.
48. Kerwin, R.W.; Patel, S.; Meldrum, B.S.; Czudek, C.; and Reynolds, G.P. Asymmetrical loss of glutamate receptor subtypes in left hippocampus in schizophrenia. Lancet, I:583-584, 1988.
49. Keshavan, M.S.; Anderson, S.; and Pettegrew, J.W. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. Journal of Psychiatric Research, 28(3):239-265, 1994.
50. Keshavan, M.S.; Pettegrew, J.W.; Panchalingam, K.S.; Kaplan, D.; and Bozik, E. Phosphorus-31 magnetic resonance spectroscopy detects altered brain metabolism before onset of schizophrenia. [Letter] Archives of General Psychiatry, 48(12):1112-1113, 1991.
51. Kety, S.S.; Rosenthal, D.; Wender, P.H.; Shulsinger, F.; and Jacobsen, B. Mental illness in the biological and adoptive families of individuals who have become schizophrenic. Behavioral Genetics, 6:219-225, 1976.
52. Klockgether, T., and Turski, L. Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia. Annals of Neurology, 34:585-593, 1993.
53. Lieberman, J.A.; Alvir, J.M.; Koreen, A.; Geisler, S.; Chakos, M.; Sheitman, B.; and Woerner, M. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology, 14(Suppl. 3):13-21, 1996.
54. Lieberman, J.A.; Jody, D.; Geisler, S.; Alvir, J.; Loebel, A.; Szymanski, S.; Woerner, M.; and Borenstein, M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry, 50:369-376, 1993.
55. Loebel, A.; Lieberman, J.A.; Alvir, J.; Geisler, S.; Koreen, A.; and Chakos, M. Time to treatment response in successive episodes of early-onset schizophrenia. [Abstract] Schizophrenia Research, 15:158, 1995.
56. Luchins, D.J.; Lewine, R.R.J.; and Meltzer, H.Y. Lateral ventricular size, psychopathology, and medication response in the psychoses. Biological Psychiatry, 19:29-45, 1984.
57. Mahadik, S.P.; Mukherjee, S.; Correnti, E.E.; and Scheffer, R. Elevated levels of lipid peroxidation products in plasma of drug-naive patients at the onset of psychosis. [Abstract] Schizophrenia Research, 15:66, 1995.
58. Mednick, S.A.; Machon, R.A.; Huttunen, M.O.; and Bonett, D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Archives of General Psychiatry, 45(2):189-192, 1988.
59. Mitchell, I.J.; Lawson, S.; Moser, B.; Laidlaw, S.M.; Cooper, A.J.; Walkinshaw, G.; and Waters, C.M. Glutamate-induced apoptosis results in a loss of striatal neurons in the Parkinsonian rat. Neuroscience, 63:1-5, 1994.
60. Mukherjee, S.; Mahadik, S.P.; Correnti, E.E.; and Scheffer, R. The antioxidant defense system at the onset of psychosis. Biological Psychiatry, 35:615-747, 1994.
61. Nasrallah, H.A.; Jacoby, C.G.; Chapman, S.; and McCalley-Whitters, M. Third ventricular enlargement on CT scans in schizophrenia: Association with cerebellar atrophy. Biological Psychiatry, 20:445-450, 1985.
62. 2 activity in schizophrenics and other psychiatric patients. Biological Psychiatry, 34:641-649, 1993.
63. O'Donnell, B.F.; Faux, S.F.; McCarley, R.W.; Kimble, M.O.; Salisbury, D.F.; Nestor, P.G.; Kikinis, R.; Jolesz, F.A.; and Shenton, M.E. Increased rate of of P300 latency prolongation with age in schizophrenia. Archives of General Psychiatry, 52:544-549, 1995.
64. Olney, J.W., and Farber, N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry, 52:998-1007, 1995.
65. Pandurangi, A.K.; Goldberg, S.C.; Brink, D.D.; Hill, M.H.; Gulati, A.N.; and Hamer, R.M. Amphetamine challenge test, response to treatment, and lateral ventricle size in schizophrenia. Biological Psychiatry, 25:207-214, 1989.
66. Pangerl, A.M.; Stuedle, A.; Jaroni, H.W.; and Gattaz, W.F. Increased lysophosphatidylcholine content in platelet membrane of schizophrenics. Schizophrenia Research, 6:134-135, 1992.
67. Peralta, V.; deLeon, J.; and Cuesta, M.J. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy. British Journal of Psychiatry, 161:335-343, 1992.
68. Perez-Polo, J.R.; Dy, P.; Westlund, K.; Hall, K.; and Livingston, K. Levels of serum nerve growth factor in schizophrenia. In: Bergsma, D., and Goldstein, A.L., eds. Birth Defects: Original Article Series. Vol. 14, No. 5. New York, NY: Liss, 1978. pp. 311-321.
69. 31P nuclear magnetic resonance spectroscopy: Neurodevelopment and schizophrenia. Schizophrenia Bulletin, 19(1):35-53, 1993.
70. Pettegrew, J.W.; Keshavan, M.S.; Panchalingam, K.; Strychor, S.; Kaplan, D.B.; Tretta, M.G.; and Allen, M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. Archives of General Psychiatry, 48:563-568, 1991.
71. Prilipko, L.L. Activation of lipid peroxidation under stress and in schizophrenia. In: Kenali, D.; Morozov, P.V.; and Toffano, G., eds. New Research Strategies in Biological Psychiatry. London, England: John Libbey, 1984.
72. Pulver, A.E.; Lasseter, V.K.; Kasch, L.; Wolyniec, P.; Nestadt, G.; Blouin, J.; Kimberland, M.; Babb, R.; Vourlis, S.; Chen, H.; Lalioti, M.; Morris, M.A.; Karayiorgou, M.; Ott, J.; Meyers, D.; Antonarakis, S.E.; Housman, D.; and Kazazian, H.H. Schizophrenia: A genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes. American Journal of Medical Genetics, 60(3):252-260, 1995.
73. Purohit, D.P.; Davidson, M.; Perl, D.P.; Powchik, P.; Haroutunian, V.H.; Bierer, L.M.; McCrystal, J.; Losonczy, M.; and Davis, K.L. Severe cognitive impairment in elderly schizophrenic patients: A clinicopathological study. Biological Psychiatry, 33:255-260, 1993.
74. Raff, M.C.; Barres, B.A.; Burne, J.F.; Coles, H.S.; Ishizaki, Y.; and Jacobson, D. Programmed cell death and the control of cell survival: Lessons from the nervous system. Science, 262:695-700, 1993.
75. Rothman, S.M., and Olney, J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Annals of Neurology, 19:105-111, 1986.
76. Sandyk, R.; Kay, S.R.; and Merriam, A.E. Atrophy of the cerebellar vermis: Relevance to the symptoms of schizophrenia. International Journal of Neuroscience, 57:205-212, 1991.
77. Sautter, F.; McDermott, B.; and Garver, D. Familial differences between neuroleptic response psychosis and delayed neuroleptic response psychosis. Biological Psychiatry, 33:15-21, 1993.
78. Scheffer, R.; Mahadik, S.P.; Correnti, E.E.; McClure, M.; and Mukherjee, S. Membrane lipid peroxidation and neurological signs in first episode psychosis. [Abstract] Biological Psychiatry, 37:681, 1995.
79. Schwarzkopf, S.B.; Olson, S.C.; Coffman, J.A.; and Nasrallah, H.A. Third and lateral ventricular volumes in schizophrenia: Support for progressive enlargement of both structures. Psychopharmacology Bulletin, 26(3):385-391, 1990.
80. Shioiri, T.; Kato, T.; Inubushi, T.; Murashita, J.; and Takahashi, S. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Research: Neuroimaging, 55(4):223-235, 1994.
81. Shoulson, I. Huntington's disease: Anti-neurotoxic therapeutic strategies. In: Fuxe, K.; Roberts, P.; and Schwarcz, R., eds. Excitotoxins. London: Macmillan Press, 1983. pp. 343-353.
82. SigmaPlot for Windows. San Rafael, CA. Jandel Scientific, 1986-1994.
83. Simon, R.P.; Swan, J.H.; Griffiths, T.; and Meldrum, B.S. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science, 226:850-852, 1984.
84. Simpson, M.D.C.; Simpson, P.S.; Royston, M.C.; and Deakin, J.F.W. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Research, 42:273-282, 1992.
85. Stanley, J.A.; Williamson, P.C.; Drost, D.J.; Carr, T.J.; Rylett, J.; Malla, A.; and Thompson, R.T. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Archives of General Psychiatry, 52:399-406, 1995.
86. 31P-MR spectroscopy study. Schizophrenia Research, 13:209-216, 1994.
87. Stevens, J.R. Abnormal reinnervation as a basis for schizophrenia: A hypothesis. Archives of General Psychiatry, 49:238-243, 1992.
88. Susser, E.; Neugebauer, R.; Hoek, H.W.; Brown, A.S.; Lin, S.; Labovitz, D.; and Gorman, J.M. Schizophrenia after prenatal famine: Further evidence. Archives of General Psychiatry, 53:25-31, 1996.
89. SYSTAT. Statistics. Version 5 edition. Evanston, IL: SYSTAT, Inc., 1992.
90. Vita, A.; Dieci, M.; Giobbio, G.M.; Azzone, P.; Garbarini, M.; Sacchetti, E.; Cesana, B.M.; and Cazzullo, C.L. CT scan abnormalities and outcome of chronic schizophrenia. American Journal of Psychiatry, 148:1577-1579, 1991.
91. Vita, A.; Giobbio, G.M.; Dieci, M.; Garbarini, M.; Morgant, C.; Comazzi, M.; and Invernizz, G. Stability of cerebral ventricular size from the appearance of the first psychotic symptoms to the later diagnosis of schizophrenia. Biological Psychiatry, 35:960-962, 1994.
92. Vita, A.; Sacchetti, E.; Calzeroni, A.; and Cazzullo, C.L. Cortical atrophy in schizophrenia: Prevalence and associated features. Schizophrenia Research, 1:329-337, 1988.
93. Waddington, J.L.; O'Callaghan, E.; Buckley, P.; Larkin, C.; Redmond, O.; Stack, J.; and Ennis, J.T. The age dependencies of MRI abnormalities in schizophrenia suggest early ventricular enlargement but later prominence of cortical atrophy. Schizophrenia Research, 5:188-189, 1991.
94. Wang, S.; Sun, C.; Walczak, C.A.; Ziegle, J.S.; Kipps, B.R.; Goldin, L.R.; and Diehl, S. Evidence for a susceptibility locus for schizophrenia on chromosome 6pter-p22. Nature Genetics, 10(1):41-46, 1995.
95. Weinberger, D.R.; Bigelow, L.B.; Kleinman, J.E.; Klein, S.T.; Rosenblatt, J.E.; and Wyatt, R.J. Cerebral ventricular enlargement in chronic schizophrenia: An association with poor response to treatment. Archives of General Psychiatry, 37:11-13, 1980.
96. Wood, K.A., and Youle, R.J. Apoptosis and free radicals. Annals of the New York Academy of Sciences, 738:400-407, 1994.
97. Woods, B.T.; Yurgelun-Todd, D.; Benes, F.M.; Frankenburg, F.R.; Pope, H.G., Jr.; and McSparren, J. Progressive ventricular enlargement in schizophrenia: Comparison to bipolar affective disorder and correlation with clinical course. Biological Psychiatry, 27:341-352, 1990.
98. Wyatt, R.J. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 17(2):325-351, 1991.
99. Yao, J.K.; van Kammen, D.P.; and Welker, J.A. Red blood cell membrane dynamics in schizophrenia: II. Fatty acid composition. Schizophrenia Research, 13:217-226, 1994.